LA JOLLA, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., President and Chief Executive Officer of the Company, will present at the BIO-Europe 2013 conference to be held in Vienna, Austria on November 4-6, 2013. Dr. Damaj is scheduled to present on Tuesday, November 5th at 10:00 a.m. local Vienna time.
Dr. Damaj will cover recent data on the Company's two main products EjectDelayTM the Company's topical treatment for premature ejaculation, and CIRCUMserumTM, its product for reduced penile sensitivity, as well as the progress in each product's launch, partnerships and commercialization.
About Innovus Pharma
Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.
Innovus Pharma has a global over the counter pipeline in sexual dysfunction and pain management including EjectDelayTM for premature ejaculation, CIRCUMserumTM for reduced penile sensitivity, ApeazTM for arthritis pain relief and XyralidTM for hemorrhoids.
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such products as EjectDelay™ and CIRCUMserumTM and to achieve its other development, commercialization and financial objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Kevin Holmes Chesapeake Group firstname.lastname@example.org T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.